Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other beta 2-containing neuronal nicotinic acetylcholine receptors (nAChRs) represent a diverse group of pentameric ligand-gated ion channels that incorporate the beta 2 subunit (encoded by the CHRNB2 gene) in combination with alpha subunits other than alpha 4, such as alpha 2, alpha 3, or alpha 6 (Source: UniProt P17677). These receptors are widely distributed throughout the central and peripheral nervous systems, where they modulate the release of various neurotransmitters, including dopamine, GABA, and glutamate. While the alpha 4 beta 2 subtype is the most prevalent high-affinity nicotine-binding receptor in the brain, these 'other' beta 2-containing receptors play specialized roles in circuits related to reward, motor control, and autonomic function (Source: PubMed PMC2629101). For instance, alpha 6 beta 2-containing receptors are highly localized in dopaminergic pathways of the striatum and are significant targets for Parkinson's disease and addiction research. Mutations in the CHRNB2 gene are specifically linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE), highlighting the receptor's role in maintaining excitatory-inhibitory balance in the cerebral cortex (Source: NIH Genetics Home Reference). Pharmacological targeting of these receptors aims to treat cognitive deficits and substance use disorders, though achieving subtype selectivity remains a major challenge to avoid off-target autonomic effects associated with alpha 3-containing variants found in ganglia.
Ligand-gated ion channel activation or modulation, leading to the influx of cations such as sodium (Na+) and calcium (Ca2+), which results in neuronal depolarization and the subsequent release of neurotransmitters like dopamine and glutamate (Source: IUPHAR/BPS Guide to Pharmacology).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal nicotinic acetylcholine receptor beta 2-containing subtypes (beta2-nAChR).